Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results